386 related articles for article (PubMed ID: 19791425)
1. Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II.
O'Connor O; Wright J; Moskowitz CH; Muzzy J; MacGregor-Cortelli B; Hamlin P; Straus D; Trehu E; Schenkein DP; Zelenetz AD
J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S21-2. PubMed ID: 19791425
[TBL] [Abstract][Full Text] [Related]
2. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
O'Connor OA; Wright J; Moskowitz C; Muzzy J; MacGregor-Cortelli B; Stubblefield M; Straus D; Portlock C; Hamlin P; Choi E; Dumetrescu O; Esseltine D; Trehu E; Adams J; Schenkein D; Zelenetz AD
J Clin Oncol; 2005 Feb; 23(4):676-84. PubMed ID: 15613699
[TBL] [Abstract][Full Text] [Related]
3. The role of bortezomib in the treatment of lymphoma.
Barr P; Fisher R; Friedberg J
Cancer Invest; 2007 Dec; 25(8):766-75. PubMed ID: 18058474
[TBL] [Abstract][Full Text] [Related]
4. Use of bortezomib in B-cell non-Hodgkin's lymphoma.
Wang M; Zhou Y; Zhang L; Nguyen CA; Romaguera J
Expert Rev Anticancer Ther; 2006 Jul; 6(7):983-91. PubMed ID: 16831071
[TBL] [Abstract][Full Text] [Related]
5. Treatment of mantle cell lymphoma: targeting the microenvironment.
Drach J; Seidl S; Kaufmann H
Expert Rev Anticancer Ther; 2005 Jun; 5(3):477-85. PubMed ID: 16001955
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibitors in non-Hodgkin's lymphoma.
Zelenetz A
J Natl Compr Canc Netw; 2005 Nov; 3 Suppl 1():S34-6. PubMed ID: 16280110
[No Abstract] [Full Text] [Related]
7. Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma.
O'Connor OA
Clin Lymphoma Myeloma; 2005 Nov; 6(3):191-9. PubMed ID: 16354324
[TBL] [Abstract][Full Text] [Related]
8. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.
Leonard JP; Furman RR; Coleman M
Int J Cancer; 2006 Sep; 119(5):971-9. PubMed ID: 16557600
[TBL] [Abstract][Full Text] [Related]
9. [Proteasome inhibitors].
Hatake K; Mishima Y; Terui Y
Gan To Kagaku Ryoho; 2004 Jul; 31(7):999-1002. PubMed ID: 15272575
[TBL] [Abstract][Full Text] [Related]
10. Mantle cell lymphoma: at last, some hope for successful innovative treatment strategies.
Fisher RI
J Clin Oncol; 2005 Feb; 23(4):657-8. PubMed ID: 15613690
[No Abstract] [Full Text] [Related]
11. Proteasome inhibitors as therapeutics.
Mitsiades CS; Mitsiades N; Hideshima T; Richardson PG; Anderson KC
Essays Biochem; 2005; 41():205-18. PubMed ID: 16250907
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibitors in cancer therapy.
Orlowski RZ
Methods Mol Biol; 2005; 301():339-50. PubMed ID: 15917644
[TBL] [Abstract][Full Text] [Related]
13. Targeting the proteasome in mantle cell lymphoma: a promising therapeutic approach.
Bogner C; Peschel C; Decker T
Leuk Lymphoma; 2006 Feb; 47(2):195-205. PubMed ID: 16321849
[TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibitors in the treatment of B-cell malignancies.
Schenkein D
Clin Lymphoma; 2002 Jun; 3(1):49-55. PubMed ID: 12141956
[TBL] [Abstract][Full Text] [Related]
15. [Proteasome inhibitors--new option in the treatment of tumor diseases].
Spicka I; Klener P
Cas Lek Cesk; 2004; 143(10):701-4. PubMed ID: 15584622
[TBL] [Abstract][Full Text] [Related]
16. The role of proteasome in malignant diseases.
Moran E; Nencioni A
J BUON; 2007 Sep; 12 Suppl 1():S95-9. PubMed ID: 17935285
[TBL] [Abstract][Full Text] [Related]
17. Molecular profiles of proteasome inhibition in plasma cell dyscrasias.
Mitsiades CS
J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S23-7. PubMed ID: 19795532
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibition for treatment of multiple myeloma: clinical update.
Stadtmauer EA
J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S10-5. PubMed ID: 19795531
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma.
Bersani F; Taulli R; Accornero P; Morotti A; Miretti S; Crepaldi T; Ponzetto C
Eur J Cancer; 2008 Apr; 44(6):876-84. PubMed ID: 18342500
[TBL] [Abstract][Full Text] [Related]
20. Combination of hyperthermia and bortezomib results in additive killing in mantle cell lymphoma cells.
Milani V; Lorenz M; Weinkauf M; Rieken M; Pastore A; Dreyling M; Issels R
Int J Hyperthermia; 2009 Jun; 25(4):262-72. PubMed ID: 19670095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]